On Wednesday, Jefferies upgraded UnitedHealth Group (NYSE:UNH) stock from a Hold rating to a Buy rating, a notable shift in the investment firm's stance on the healthcare giant. Accompanying the upgrade, Jefferies also increased the price target for UnitedHealth Group to $647, a significant rise from the previous target of $481.
The analyst cited several factors contributing to the positive outlook for UnitedHealth Group. The near-term medical loss ratio (MLR) may not be entirely transparent, but it appears sufficiently predictable in the first and second quarters to shift focus towards a growth outlook for 2025 that is seen as favorable and showing improvement.
The assessment points to UnitedHealth Group's potential to achieve a unique combination of strong Medicare Advantage (MA) growth alongside better margins in 2025. This is expected to support growth in Optum Health and contribute to an enhanced valuation of the company's shares.
Jefferies' analysis suggests that if UnitedHealth revisits its five-year relative multiple of approximately 1x the S&P 500, the stock's value could increase by 18%. The firm's decision to upgrade the stock to Buy and increase the price target to $647 reflects confidence in UnitedHealth's future performance and market position.
In other recent news, UnitedHealth Group is facing multiple challenges. TD Cowen has reiterated its Buy rating on UnitedHealth's stock, maintaining confidence in the company's performance despite ongoing Medicare Advantage and Medicaid trends.
However, the company is also under scrutiny from the Federal Trade Commission (FTC) over its pharmacy-benefit management pricing strategies, along with Cigna (NYSE:CI) and CVS Health (NYSE:CVS).
Furthermore, UnitedHealth recently experienced a significant cyberattack on its Change Healthcare (NASDAQ:CHNG) unit, compromising the private data of an estimated one-third of Americans.
In response to this, the Centers for Medicare and Medicaid Services (CMS) decided to end the advance payments program for Medicare providers and suppliers affected by service disruptions at Change Healthcare.
On a positive note, HSBC upgraded UnitedHealth stock from a Hold to a Buy rating, reflecting its confidence in the company's future market performance. Lastly, during its 2024 annual shareholder meeting, UnitedHealth announced the election of its Board of Directors and the authorization of a $2.10 per share cash dividend.
InvestingPro Insights
In light of the recent upgrade by Jefferies, investors may find additional context in the latest data and analysis from InvestingPro. UnitedHealth Group (NYSE:UNH) showcases a robust market capitalization of $505.17 billion, affirming its significant presence in the healthcare industry. The company's P/E ratio stands at 34.05, indicating a premium valuation that aligns with its status as a leading healthcare provider. Notably, UnitedHealth has demonstrated a solid revenue growth of 10.59% over the last twelve months as of Q2 2024, reflecting its strong operational performance.
InvestingPro Tips highlight that UnitedHealth Group has raised its dividend for 14 consecutive years, showcasing a commitment to shareholder returns. Additionally, the company's recent price performance has been strong, with a notable 9.57% total return over the past week, indicating positive investor sentiment. For those considering a deeper dive into UnitedHealth's prospects, InvestingPro offers numerous tips, including insights into analyst revisions, stock volatility, industry position, and financial health. With an additional 16 tips available on InvestingPro, investors can gain a comprehensive understanding of the company's dynamics. To access these insights and more, consider using the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.